Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen J. Hodges is active.

Publication


Featured researches published by Stephen J. Hodges.


Liver Transplantation | 2004

Pathophysiological effects of albumin dialysis in acute‐on‐chronic liver failure: A randomized controlled study

Sambit Sen; Nathan Davies; Rajeshwar P. Mookerjee; Lisa M. Cheshire; Stephen J. Hodges; Roger Williams; Rajiv Jalan

The pathophysiological basis of acute‐on‐chronic liver failure (ACLF) is unclear but systemic inflammatory response is thought to be important. In patients with ACLF, the molecular adsorbents recirculating system (MARS) improves individual organ function, but the effect of MARS on the proposed mediators of systemic inflammatory response is unclear. The present study was designed to determine the effect of MARS on the cytokine profile, oxidative stress, nitric oxide, and ammonia. A total of 18 patients with alcohol‐related ACLF due to inflammation‐related precipitants were randomized to receive standard medical therapy (SMT) alone, or with MARS therapy over 7 days. Plasma cytokines, malondialdehyde (MDA), free radical production, nitrate / nitrite (NOx), and ammonia were measured. Encephalopathy improved significantly with MARS (P < .01), but not with SMT. Mean arterial pressure and renal function remained unchanged. No significant change of plasma cytokines and ammonia levels were observed in either group. Plasma MDA levels did not change either. There was a fall in NOx (P < .05) with MARS, but not with SMT. In conclusion, in inflammation‐related ACLF patients, albumin dialysis using MARS results in improvement of encephalopathy, independent of changes of ammonia or cytokines, without improving blood pressure or renal function. These results should temper the liberal use of MARS until further data is available. (Liver Transpl 2004;10:1109–1119.)


Journal of Hepatology | 2003

Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis

Herbert Tilg; Rajiv Jalan; Arthur Kaser; Nathan Davies; Felix Offner; Stephen J. Hodges; Othmar Ludwiczek; Debbie L. Shawcross; Heinz Zoller; Akeel Alisa; Rajeshwar P. Mookerjee; Ivo Graziadei; Christian Datz; Michael H. Trauner; Detlef Schuppan; Peter Obrist; Wolfgang Vogel; Roger Williams

BACKGROUND/AIMS Severe alcoholic hepatitis (AH) is associated with high mortality. Tumor necrosis factor-alpha (TNFalpha) has been demonstrated to play an important role in its pathophysiology. METHODS Twelve patients with biopsy-confirmed AH and a Maddrey discriminant factor >32 were treated with a single infusion of the anti-TNF monoclonal antibody Infliximab at a dose of 5mg/kg body weight. Serial measurements were made for various cytokines using specific enzyme-linked immunoassays (ELISA). In four patients, liver biopsy samples were available pretreatment and on day+28 of therapy. RESULTS Ten of the 12 patients are alive at a median of 15 (12-20) months. Two patients died within 30 days from septicemia. Serum bilirubin levels, Maddrey score, neutrophil count and C-reactive protein fell significantly within the first month. There was an early, though not significant, decrease in plasma levels of proinflammatory cytokines (interleukins (IL)-1beta, IL-6, IL-8, interferon-gamma), whereas plasma levels of TNFalpha remained near the sensitivity limit of the assay throughout the treatment course. While TNFalpha mRNA expression in the liver did not change, expression of IL-8, a cytokine regulated mainly by TNFalpha, was almost absent on day+28. CONCLUSIONS Our data suggest that randomized controlled trials of anti-TNF antibody in severe AH are warranted.


Hepatology | 2007

Endotoxemia produces coma and brain swelling in bile duct ligated rats

Gavin Wright; Nathan Davies; Debbie L. Shawcross; Stephen J. Hodges; Claudia Zwingmann; Heather F. Brooks; Ali R. Mani; David Harry; Vanessa Stadlbauer; Zheng Zou; Roger Williams; Ceri Davies; Kevin Moore; Rajiv Jalan

This study explores the hypothesis that the inflammatory response induced by administration of lipopolysaccharide (LPS) exacerbates brain edema in cirrhotic rats; and if so whether this is associated with altered brain metabolism of ammonia or anatomical disturbance of the blood‐brain barrier. Adult Sprague‐Dawley rats 4 weeks after bile duct ligation (BDL)/Sham‐operation, or naïve rats fed a hyperammonemic diet (HD), were injected with LPS (0.5 mg/kg, intraperitoneally) or saline, and killed 3 hours later. LPS administration increased brain water in HD, BDL, and sham‐operated groups significantly (P < 0.05), but this was associated with progression to pre‐coma stages only in BDL rats. LPS induced cytotoxic brain swelling and maintained anatomical integrity of the blood‐brain barrier. Plasma/brain ammonia levels were higher in HD and BDL rats than in sham‐operated controls and did not change with LPS administration. Brain glutamine/myoinositol ratio was increased in the HD group but reduced in the BDL animals. There was a background pro‐inflammatory cytokine response in the brains of cirrhotic rats, and plasma/brain tumor necrosis factor alpha (TNF‐α) and IL‐6 significantly increased in LPS‐treated animals. Plasma nitrite/nitrate levels increased significantly in LPS groups compared with non‐LPS controls; however, frontal cortex nitrotyrosine levels only increased in the BDL + LPS rats (P < 0.005 versus BDL controls). Conclusion: Injection of LPS into cirrhotic rats induces pre‐coma and exacerbates cytotoxic edema because of the synergistic effect of hyperammonemia and the induced inflammatory response. Although the exact mechanism of how hyperammonemia and LPS facilitate cytotoxic edema and pre‐coma in cirrhosis is not clear, our data support an important role for the nitrosation of brain proteins. (HEPATOLOGY 2007.)


Hepatology | 2008

Ammonia impairs neutrophil phagocytic function in liver disease

Debbie L. Shawcross; Gavin Wright; Vanessa Stadlbauer; Stephen J. Hodges; Nathan Davies; Caroline P.D. Wheeler-Jones; Andrew A. Pitsillides; Rajiv Jalan

Hyperammonemia is a feature of liver failure, which is associated with increased risk of infection. The aims of the present study were to determine in vitro, in rats fed an ammoniagenic diet and in patients with cirrhosis, whether induction of hyperammonemia results in neutrophil dysfunction. As hyperammonemia produces cell swelling, we explored the role of the osmoregulating, p38 mitogen‐activated protein kinase (p38MAPK) pathway in mediating this neutrophil dysfunction. Neutrophils were isolated from blood of healthy volunteers and incubated with either 75 μM ammonia or phosphate‐buffered saline. Both groups were studied under hyponatremic conditions and/or with the addition of p38MAPK modulators. Neutrophil phagocytosis was measured in naive rats and rats fed an ammoniagenic diet and in patients with stable cirrhosis given placebo (n = 8) or an amino acid solution inducing hyperammonemia (n = 8). Cell volume and phagocytosis was analyzed by fluorescent‐activated cell sorting using fluorescein isothiocyanate–labeled E. coli. p38MAPK phosphorylation was measured by western blotting. In healthy neutrophils incubated with ammonia and in rats fed an ammoniagenic diet, neutrophils showed evidence of swelling, impaired phagocytosis, and increased spontaneous oxidative burst compared to controls. Phagocytosis was significantly impaired in patients with induced hyperammonemia compared to placebo. The effects of hyperammonemia and hyponatremia were synergistic. The p38MAPK intracellular signaling pathways were activated in healthy neutrophils exposed to ammonia in association with increased burst activity. Neutrophil phagocytic dysfunction was abrogated by the addition of a p38MAPK agonist. Conclusion: Ammonia produces neutrophil swelling and impairs neutrophil phagocytosis. The p38MAPK intracellular signaling pathway has been shown to be important in mediating the ammonia‐induced neutrophil dysfunction. (HEPATOLOGY 2008.)


Hepatology | 2007

Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis

Rajeshwar P. Mookerjee; Mohammed Malaki; Nathan Davies; Stephen J. Hodges; R. Neil Dalton; Charles Turner; Sambit Sen; Roger Williams; James Leiper; Patrick Vallance; Rajiv Jalan

Previous studies suggest reduced hepatic endothelial nitric oxide synthase activity contributes to increased intrahepatic resistance. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, undergoes hepatic metabolism via dimethylarginine‐dimethylamino‐hydrolase, and is derived by the action of protein‐arginine‐methyltransferases. Our study assessed whether ADMA, and its stereo‐isomer symmetric dimethylarginine (SDMA), are increased in alcoholic hepatitis patients, and determined any relationship with severity of portal hypertension (hepatic venous pressure gradient measurement) and outcome. Fifty‐two patients with decompensated alcoholic cirrhosis were studied, 27 with acute alcoholic hepatitis and cirrhosis, in whom hepatic venous pressure gradient was higher (P = 0.001) than cirrhosis alone, and correlated with ADMA measurement. Plasma ADMA and SDMA were significantly higher in alcoholic hepatitis patients and in nonsurvivors. Dimethylarginine‐dimethylamino‐hydrolase protein expression was reduced and protein‐arginine‐methyltransferase‐1 increased in alcoholic hepatitis livers. ADMA, SDMA and their combined sum, which we termed a dimethylarginine score, were better predictors of outcome compared with Pugh score, MELD and Maddreys discriminant‐function. Conclusion: Alcoholic hepatitis patients have higher portal pressures associated with increased ADMA, which may result from both decreased breakdown (decreased hepatic dimethylarginine‐dimethylamino‐hydrolase) and/or increased production. Elevated dimethylarginines may serve as important biological markers of deleterious outcome in alcoholic hepatitis. (HEPATOLOGY 2007;45:62–71.)


Critical Care Medicine | 2006

EFFECT OF ALBUMIN DIALYSIS ON INTRACRANIAL PRESSURE INCREASE IN PIGS WITH ACUTE LIVER FAILURE: A RANDOMIZED STUDY

Sambit Sen; Christopher F. Rose; Lars M. Ytrebø; Nathan Davies; Geir I. Nedredal; Synnøve Sæterstad Drevland; Marianne Kjønnø; Frits W. Prinzen; Stephen J. Hodges; Nicolaas E. P. Deutz; Roger Williams; Roger F. Butterworth; Arthur Revhaug; Rajiv Jalan

Background:Increased intracranial pressure (ICP) worsens the outcome of acute liver failure (ALF). This study investigates the underlying pathophysiological mechanisms and evaluates the therapeutic effect of albumin dialysis in ALF with use of the Molecular Adsorbents Recirculating System without hemofiltration/dialysis (modified, M-MARS). Methods:Pigs were randomized into three groups: sham, ALF, and ALF + M-MARS. ALF was induced by hepatic devascularization (time = 0). M-MARS began at time = 2 and ended with the experiment at time = 6. ICP, arterial ammonia, brain water, cerebral blood flow (CBF), and plasma inflammatory markers were measured. Results:ICP and arterial ammonia increased significantly over 6 hrs in the ALF group, in comparison with the sham group. M-MARS attenuated (did not normalize) the increased ICP in the ALF group, whereas arterial ammonia was unaltered by M-MARS. Brain water in the frontal cortex (grey matter) and in the subcortical white matter at 6 hrs was significantly higher in the ALF group than in the sham group. M-MARS prevented a rise in water content, but only in white matter. CBF and inflammatory mediators remained unchanged in all groups. Conclusion:The initial development of cerebral edema and increased ICP occurs independently of CBF changes in this noninflammatory model of ALF. Factor(s) other than or in addition to hyperammonemia are important, however, and may be more amenable to alteration by albumin dialysis.


Hepatology | 2009

L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats

Nathan Davies; Gavin Wright; Lars M. Ytrebø; Vanessa Stadlbauer; Ole-Martin Fuskevåg; Claudia Zwingmann; D. Ceri Davies; Abeba Habtesion; Stephen J. Hodges; Rajiv Jalan

Treatment of hyperammonemia and hepatic encephalopathy in cirrhosis is an unmet clinical need. The aims of this study were to determine whether L‐ornithine and phenylacetate/phenylbutyrate (administered as the pro‐drug phenylbutyrate) (OP) combined are synergistic and produce sustained reduction in ammonia by L‐ornithine acting as a substrate for glutamine synthesis, thereby detoxifying ammonia, and the phenylacetate excreting the ornithine‐derived glutamine as phenylacetylglutamine in the urine. Sprague‐Dawley rats were studied 4 weeks after bile duct ligation (BDL) or sham operation. Study 1: Three hours before termination, an internal carotid sampling catheter was inserted, and intraperitoneal saline (placebo), OP, phenylbutyrate, or L‐ornithine were administered after randomization. BDL was associated with significantly higher arterial ammonia and brain water and lower brain myoinositol (P < 0.01, respectively), compared with sham‐operated controls, which was significantly improved in the OP‐treated animals; arterial ammonia (P < 0.001), brain water (P < 0.05), brain myoinositol (P < 0.001), and urinary phenylacetylglutamine (P < 0.01). Individually, L‐ornithine or phenylbutyrate were similar to the BDL group. In study 2, BDL rats were randomized to saline or OP administered intraperitoneally for 6 hours or 3, 5, or 10 days and were sacrificed between 4.5 and 5 weeks. The results showed that the administration of OP was associated with sustained reduction in arterial ammonia (P < 0.01) and brain water (P < 0.01) and markedly increased arterial glutamine (P < 0.01) and urinary excretion of phenylacetylglutamine (P < 0.01) in each of the OP treated groups. Conclusion: The results of this study provide proof of the concept that L‐ornithine and phenylbutyrate/phenylacetate act synergistically to produce sustained improvement in arterial ammonia, its brain metabolism, and brain water in cirrhotic rats. (HEPATOLOGY 2009.)


Liver Transplantation | 2007

Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure.

Rajeshwar P. Mookerjee; R. Neil Dalton; Nathan Davies; Stephen J. Hodges; Charles Turner; Roger Williams; Rajiv Jalan

Acute liver failure (ALF) is characterized by rapid progressive organ failure and poor outcome. The pathophysiology of multiorgan dysfunction in ALF remains unclear but increased systemic inflammatory response is believed to be an important determining factor. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, results from proteolysis and the liver is a major site for its metabolism. ADMA has been shown to independently predict outcome in multiorgan failure associated with severe liver dysfunction. In this study, we tested the hypothesis that proinflammatory cytokine driven responses are important in modulating ADMA levels in patients with acetaminophen‐induced ALF. Blood samples were collected from 10 ALF patients (grade IV encephalopathy) from admission until the time of transplantation or death, and assayed for cytokines and ADMA. A total of 8 patients required treatment for raised intracranial pressure and all patients were managed with standard of care, including full mechanical ventilation and veno‐venous hemofiltration. ADMA levels were markedly higher in ALF patients compared to age‐matched controls (P < 0.001) and correlated with the levels of proinflammatory cytokines. In pretransplantation patients undergoing hepatic venous catheterization, we demonstrated no significant uptake of ADMA across the failing liver. However, following liver transplantation, ADMA levels reduced acutely. A timed study of ADMA levels during transplantation demonstrated a slight increase during the anhepatic phase but a marked and sustained reduction in ADMA following liver reperfusion. In conclusion, our data show a significant correlation between ADMA levels and proinflammatory cytokines, supporting a hypothesis that proinflammatory cytokines may regulate ADMA metabolism in ALF. Liver Transpl 13:400–405, 2007.


Journal of Hepatology | 2010

Role of aquaporin-4 in the development of brain oedema in liver failure

Gavin Wright; Robin Soper; Heather F. Brooks; Vanessa Stadlbauer; Balasubramaniyan Vairappan; Nathan Davies; Fausto Andreola; Stephen J. Hodges; Raymond Moss; D. Ceri Davies; Rajiv Jalan

BACKGROUND & AIMS Liver failure is associated with progressive cytotoxic brain oedema (astrocyte swelling), which underlies hepatic encephalopathy (HE). Ammonia and superimposed inflammation are key synergistic factors in HE, but the mechanism(s) involved remain unknown. We aimed to determine whether aquaporin-4 (AQP4), an astrocyte endfeet bi-directional water channel, is associated with the brain oedema of HE. METHOD Rats (n=60) received sham-operation (sham), 5 days hyperammonaemia-inducing diet (HD), galactosamine (GALN) induced acute liver failure (ALF), 4 weeks bile duct-ligation (BDL) induced cirrhosis, or caecal ligation and puncture (CLP), a 24h model of bacterial peritonitis. Rats from every group (except CLP) were randomised to receive intraperitoneal injections of lipopolysaccharide (LPS; 1mg/kg) or saline, prior to termination 3h later. Brain water, AQP4 protein expression (western blot) and AQP4 localisation by immunogold electron microscopy were investigated. RESULTS Significant hyperammonaemia was observed in saline-injected BDL (p<0.05), GALN (p<0.01), and HD (p<0.01), compared to sham rats. LPS injection did not affect arterial ammonia or plasma biochemistry in any of the treatment groups. Increased brain water was observed in saline-injected GALN (p<0.05), HD (p<0.01), and CLP (p<0.001) compared to sham rats. Brain water was numerically increased in BDL rats, but this failed to reach significance (p=0.09). LPS treatment further increased oedema significantly in all treatment groups (p<0.05, respectively). AQP4 expression was significantly increased in saline-injected BDL (p<0.05), but not other treatment groups, compared to sham rats. Membrane polarisation was maintained in BDL rats. CONCLUSION The results suggest that AQP4 is not directly associated with the development of brain oedema in liver failure, hyperammonaemia, or sepsis. In cirrhosis, there is increased AQP4 protein expression, but membrane polarisation, is maintained, possibly in a compensatory attempt to limit severe brain oedema.


FEBS Letters | 2006

Hepatic guanylate cyclase activity is decreased in a model of cirrhosis : A quantitative cytochemistry study

Nathan Davies; Stephen J. Hodges; Andrew A. Pitsillides; Rajeshwar P. Mookerjee; Rajiv Jalan; Siroos Mehdizadeh

The production of nitric oxide (NO) in liver disease and its role in vascular control has been a subject of much interest in recent years. However, the activity of guanylate cyclase (GC), the enzyme activated by NO has received little attention with regard to liver disease. In this study we have utilised a quantitative cytochemical technique to examine the activity of GC on a per cell basis in a rat model of cirrhosis. Our results show a significant reduction in GC activity, indicating that vascular regulation is likely to be substantially affected irrespective of NO generation in this disease model.

Collaboration


Dive into the Stephen J. Hodges's collaboration.

Top Co-Authors

Avatar

Nathan Davies

University College London

View shared research outputs
Top Co-Authors

Avatar

Rajiv Jalan

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roger Williams

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Sambit Sen

University College London

View shared research outputs
Top Co-Authors

Avatar

Gavin Wright

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robin Soper

Royal Veterinary College

View shared research outputs
Researchain Logo
Decentralizing Knowledge